Yongmao Holdings (SGX:BKX) Full Year 2025 Results

Key Financial Results

• Revenue: CN¥880.3m (up 11% from FY 2024).
• Net income: CN¥33.2m (down 23% from FY 2024).
• Profit margin: 3.8% (down from 5.4% in FY 2024).
• EPS: CN¥0.37 (down from CN¥0.48 in FY 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the The People's Republic of China (PRC) segment contributing a total revenue of CN¥925.6m (105% of total revenue). Notably, cost of sales worth CN¥626.9m amounted to 71% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥102.8m (47% of total expenses). Explore how BKX's revenue and expenses shape its earnings.

Yongmao Holdings shares are up 11% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 5 warning signs for Yongmao Holdings (2 can't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.